AMAN U BUZDAR to Estrogen Antagonists
This is a "connection" page, showing publications AMAN U BUZDAR has written about Estrogen Antagonists.
Connection Strength
2.534
-
Combination endocrine treatments unproven in breast cancer. Lancet Oncol. 2013 Sep; 14(10):917-8.
Score: 0.412
-
Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer. Drugs Today (Barc). 2008 Sep; 44(9):679-92.
Score: 0.293
-
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002 Aug 15; 20(16):3386-95.
Score: 0.193
-
Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat. 2002 May; 73(2):161-75.
Score: 0.189
-
Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. J Clin Oncol. 2001 Apr 01; 19(7):2002-9.
Score: 0.175
-
Differences in toxicity findings for antiestrogens. J Clin Oncol. 1998 May; 16(5):1999-2000.
Score: 0.143
-
Update on endocrine therapy for breast cancer. Clin Cancer Res. 1998 Mar; 4(3):527-34.
Score: 0.141
-
Aromatase inhibitors: current status. Am J Clin Oncol. 1995 Oct; 18(5):407-17.
Score: 0.120
-
Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1994; 33(4):313-6.
Score: 0.106
-
Anastrozole. Expert Opin Drug Saf. 2010 Nov; 9(6):995-1003.
Score: 0.085
-
Current status of endocrine treatment of carcinoma of the breast. Semin Surg Oncol. 1990; 6(2):77-82.
Score: 0.080
-
Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology. 1988; 45(5):344-5.
Score: 0.070
-
Distribution of (7alpha)-21-[4-[(diethylamino) methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol-20-[14C]2-hydroxy-1,2,3-propanetricarboxylate ([14C]TAS-108) and its metabolites after single oral administration to rats bearing 7,12-dimethylbenz(alpha)anthracene-induced mammary tumor. Drug Metab Dispos. 2006 Feb; 34(2):331-8.
Score: 0.060
-
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):861s-4s.
Score: 0.057
-
Tamoxifen versus aromatase inhibitors for breast cancer prevention. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):925s-30s.
Score: 0.057
-
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005 Jan 1-7; 365(9453):60-2.
Score: 0.057
-
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 2003 Jul 15; 98(2):229-38.
Score: 0.051
-
Preliminary data from ongoing adjuvant aromatase inhibitor trials. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4397s-4401s; discussion 4411s-4412s.
Score: 0.046
-
Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s.
Score: 0.046
-
Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol. 2001 Jun; 28(3):291-304.
Score: 0.044
-
Combination endocrine therapy in the management of breast cancer. Oncologist. 2001; 6(6):538-46.
Score: 0.043
-
Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer. 2000 May 01; 88(9):2054-60.
Score: 0.041
-
Trioxifene mesylate in the treatment of advanced breast cancer. Cancer. 1986 Jan 01; 57(1):40-3.
Score: 0.015
-
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer. J Surg Oncol. 1997 Nov; 66(3):215-20.
Score: 0.009